Outcomes included ASDAS-CRP (Clinically Important Improvement (CII)/MI/inactive disease), Assessment of SpondyloArthritis International Society criteria (ASAS 20/40), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Ankylosing Spondylitis Quality of Life (ASQoL), and 36-Item Short-Form Health Survey (SF-36); safety was monitored per Common Terminology Criteria for Adverse Events (CTCAE) v5.0. This evidence concerns the gene CRP and spondylitis.